COMP <GO>
MMED vs ABBV // 10Y YIELD & FRED MACRO BETA
MiniMed Group Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: MMED 3
— ABBV 11
▲ 10Y YIELD & FRED MACRO BETA LEADER: ABBV
LAST: $18.28 (-5.04%) • MKT CAP: $5.42B
macro-sensitivity
1.05
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
macro-sensitivity
1.15
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MMED VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MMED | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 54.20% | 70.20% | -16.00 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -3.90% | 29.00% | -32.90 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -7.75% | 3.47% | -11.22 | ABBV | /fcf-yield <GO> |
| Operating Margin | -6.10% | 24.60% | -30.70 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -10.70% | 6.90% | -17.60 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 14.30% | 8.60% | +5.70 | MMED | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.82 | 5.33 | -0.51 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.10% | 7.40% | -0.30 | MMED | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 43.8 | 72.8 | -28.96 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | 1.05 | 1.15 | -0.10 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 24.0x | 113.1x | -89.10 | MMED | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.42B | $513.86B | -$508.44B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MMED REV | ABBV REV | MMED GROSS % | ABBV GROSS % | MMED FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.10B | $61.16B | 54.2% | 70.2% | -$420.0M | $17.82B |
| FY 2024 | $2.71B | $56.33B | 56.3% | 70.0% | -$53.0M | $17.83B |
| FY 2023 | $2.47B | $54.32B | 44.0% | 44.0% | -$70.1M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MMED // BETA 1.05
ABBV // BETA 1.15